TY  - JOUR
T1  - Pre-Clinical Investigation of the Effect of Xanthine Oxidase Inhibitors on the Bioavailability of 6 Mercaptopurine
A1  - Anas Salman Ibrahim Al Suwaileh
A1  - Pavan Kumar Pavagada Sreenivasalu
A1  - Sibghatullah Muhammad Ali Sangi
A1  - B Vivek
A1  - T S Roopashree
A1  - Shaik Sadik
A1  - Sreeharsha Nagaraja
A1  - Sheeba Kumari
JF  - Journal of Biochemical Technology
JO  - J Biochem Technol
SN  - 0974-2328
Y1  - 2025
VL  - 16
IS  - 4
DO  - 10.51847/KVAbKC8mjQ
SP  - 75
EP  - 82
N2  - 6 Mercaptopurine (6MP) is extensively utilized in oncology and inflammatory disorders such as acute lymphoblastic leukemia (ALL) and inflammatory bowel disease (IBD). Xanthine oxidase inhibitors (allopurinol and febuxostat), utilized as first-line treatments for hyperuricemia, may affect the absorption of 6-mercaptopurine (6MP). This study aims to assess the impact of allopurinol and febuxostat on the oral bioavailability of 6-mercaptopurine (MP). Allopurinol and febuxostat were evaluated for their effects on the plasma levels of 6MP. Three cohorts of healthy rabbits were assigned to an experimental protocol involving varying dosages of 6MP: 10 mg/kg, 20 mg/kg allopurinol, and 30 mg/kg febuxostat. The hematological data indicate that allopurinol pretreatment markedly enhances 6MP bioavailability, necessitating meticulous dosage modifications. Administering 6MP alongside XOIs necessitates a substantial reduction in dosage, typically to one-third of the standard level, to prevent severe adverse effects. To guarantee patient safety and therapeutic effectiveness, stringent monitoring and personalized dosages are essential.
UR  - https://jbiochemtech.com/article/pre-clinical-investigation-of-the-effect-of-xanthine-oxidase-inhibitors-on-the-bioavailability-of-6-g1zqd6vcpbpi4e0
ER  -